Program
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928
Its studies are mostly in Ovarian Neoplasms, led by TeneoSeven.
Furthest: phase 1, since Jul 2, 20261 company-led study, 1 open or runningNext primary completion: Jun 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TeneoSeven | 11 open or running | phase 1since Jul 2, 2026 | Jul 2, 2026 | Jun 2028phase 1 · NCT07690189 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 2, 2026First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT07690189 · 90 planned · United States
Ahead
- Jun 2028Primary completion: phase 1 study in Ovarian NeoplasmsNCT07690189
TargetBeta
“A bispecific T-cell engaging (TCE) antibody directed against the tumor-associated antigen (TAA) folate receptor alpha (FRa; FolRa; FOLR1) and the T-cell surface antigen CD3, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07690189Ovarian Neoplasms · United States | 1 | Recruiting | Jun 2028 | 90 |
How it is read
Names in the registry
- “NTB-928”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.